Skip to content
6 physician-led programs. Know your costs before you begin.See what we treat
GIP + GLP-1 receptor agonist

Zepbound

tirzepatide

FDA-approved for chronic weight management and for obstructive sleep apnea in adults with obesity. Once-weekly subcutaneous injection.

Mechanism

How it works

Tirzepatide activates two appetite-regulating hormone receptors, GIP and GLP-1, instead of one. It slows gastric emptying, reduces appetite, and improves glucose handling.

Technical detail
Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors with a half-life of approximately 5 days. Combined incretin action produces glucose-dependent insulin release, central appetite suppression, and slowed gastric emptying.
At Vayra

How we use it

Zepbound is part of our GLP-1 Weight Optimization program for patients meeting on-label criteria for chronic weight management or obesity-related obstructive sleep apnea. Continuity is a priority, you will see the same physician whenever clinically possible; 45-min initial visit, 30-min monthly check-ins.

Route & titration

What to expect

Once-weekly subcutaneous self-administered injection. Dose escalation per the FDA-approved schedule: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, advancing approximately monthly per tolerance. Maintenance is individualized to 5, 10, or 15 mg weekly.

Safety

Adverse effects and contraindications

Common
  • Nausea, most pronounced during titration
  • Diarrhea
  • Constipation
  • Reduced appetite
  • Fatigue
Infrequent
  • Headache
  • Injection-site irritation
  • Dyspepsia
Serious
  • Pancreatitis, discontinue if suspected
  • Gallbladder events
  • Acute kidney injury secondary to volume depletion during severe vomiting
  • Thyroid C-cell tumors, boxed warning per the FDA label
Contraindications
  • Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
  • Pregnancy or planned pregnancy in the next 2 months
  • Severe gastroparesis
Evidence

What the literature says

Published trials of tirzepatide for chronic weight management (the SURMOUNT program) report mean weight reduction at one year. As with all GLP-1 RA therapy, effects depend on continued use. Vayra does not claim specific outcomes.

Dispensing

How it reaches you

Branded Zepbound is prescribed and dispensed through a separately licensed retail/specialty pharmacy partner. Your medication is priced separately and shown with your total, alongside your physician care and lab review.

Your health info stays private (HIPAA)
Licensed doctors in 40+ states
Filled by a licensed pharmacy
No insurance needed · Use your FSA or HSA

Begin a documented physician visit.

Prescribing is the outcome of a clinical encounter, not a checkout flow. Your assessment takes about eight minutes; nothing is billed until you and your physician agree on a protocol.

See if Vayra is right for you

Eight minutes to start. A lifetime of difference.

A Vayra-affiliated physician reviews your intake, typically within 24 to 48 hours. No insurance billed. No minimum term.